+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Personalized Nanotechnology for Cell & Gene Therapies Market - Global Forecast 2026-2032- Product Image
Personalized Nanotechnology for Cell & Gene Therapies Market - Global Forecast 2026-2032- Product Image
Sale

Personalized Nanotechnology for Cell & Gene Therapies Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6055636
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Personalized Nanotechnology for Cell & Gene Therapies Market is projected to reach USD 2.04 Billion in 2026. It is expected to continue growing at a CAGR of 14.42%, reaching USD 4.57 Billion by 2032.

Personalized Nanotechnology Is Reshaping Cell and Gene Therapy Delivery

Personalized nanotechnology applies engineered nanoparticles, lipid systems, polymers, and related platforms to improve the delivery, protection, targeting, and manufacturing of cell and gene therapies. Its relevance is increasing as developers address tissue specificity, immune interactions, dose control, repeat administration, and the practical constraints of producing individualized treatments.

The field spans nucleic-acid delivery, ex vivo cell engineering, in vivo gene modulation, biomarker-guided formulation, and process analytics. Progress depends on coordinated advances in materials science, molecular biology, clinical development, quality systems, and regulatory science rather than on any single technology.

Convergence of Precision Medicine, Advanced Materials, and Scalable Manufacturing

The landscape is shifting from generalized delivery systems toward designs informed by patient biology, disease subtype, target tissue, and treatment context. This change is encouraging more selective payload release, improved control of biodistribution, and closer alignment between formulation development and companion diagnostic strategies.

At the same time, commercialization requirements are raising the importance of reproducible particle characterization, raw-material control, aseptic processing, analytical comparability, and supply-chain resilience. Ex vivo workflows remain important, while in vivo approaches are increasing demand for delivery systems that can demonstrate consistent performance across diverse patient populations.

Artificial Intelligence Accelerates Design, Testing, and Personalization

Artificial intelligence can support nanotechnology research by linking formulation variables with potency, stability, biodistribution, toxicity, and manufacturability data. Machine-learning models may help prioritize candidates, identify meaningful material attributes, optimize experimental designs, and detect relationships that are difficult to resolve through conventional trial-and-error development.

Its value is limited by data quality, inconsistent assay protocols, small datasets, weak external validation, and the need for interpretable evidence. Industry leaders therefore need governed data architectures, documented model performance, human scientific oversight, and prospective validation before using AI outputs in regulated development or patient-selection decisions.

Regional Ecosystems Differ in Translation, Regulation, and Manufacturing Readiness

North America combines strong biomedical research, venture activity, clinical infrastructure, and regulatory experience in advanced therapies, while Latin America is building capabilities through specialized hospitals, academic partnerships, and localized manufacturing initiatives. Europe benefits from coordinated scientific networks and sophisticated quality frameworks, although cross-border implementation and reimbursement requirements can remain complex.

Asia-Pacific includes highly active research and manufacturing ecosystems, particularly in China, Japan, South Korea, Australia, and India, with differing regulatory pathways and levels of infrastructure. The Middle East is expanding translational health capacity and strategic investment, while Africa’s progress is shaped by uneven laboratory access, workforce constraints, disease priorities, and the need for affordable, locally adaptable delivery platforms.

International Groups Shape Standards, Trade, Research, and Access Conditions

ASEAN cooperation can support regional clinical networks, technology transfer, and harmonized approaches to advanced-therapy manufacturing, while BRICS members bring substantial scientific, industrial, and public-health capacity with varied regulatory systems. The European Union provides a framework for collaborative research and market authorization, but implementation still depends on national health systems and manufacturing capabilities.

The G7 remains influential in research funding, regulatory dialogue, and supply-chain policy. GCC states are strengthening biomedical infrastructure and investment capacity, whereas NATO-related cooperation can affect dual-use technology governance, biosecurity, logistics, and scientific collaboration. Across these groups, alignment on quality standards, data exchange, and responsible technology transfer is central to reducing fragmentation.

Country Capabilities Range from Mature Translation to Capacity-Building Priorities

The United States and Canada have established research, clinical, and manufacturing ecosystems for advanced therapies. The United Kingdom, Germany, France, Italy, and Spain contribute strong academic, pharmaceutical, regulatory, and hospital capabilities, with continued attention to cross-border evidence generation and patient access. Australia supports translational research through advanced clinical and scientific institutions.

China, Japan, and South Korea are advancing nanomedicine, biologics manufacturing, and clinical translation through substantial research and industrial programs. India is expanding biotechnology and cost-conscious manufacturing capabilities. Brazil and Mexico are developing regional research and production networks, while Russia retains scientific capacity but faces constraints linked to international collaboration and access to specialized inputs. National readiness remains dependent on regulation, skilled personnel, quality infrastructure, and sustainable reimbursement.

Prioritize Validated Platforms, Interoperable Data, and Manufacturing Discipline

Industry leaders should define target product profiles that connect patient characteristics, payload requirements, delivery route, safety objectives, and manufacturing constraints from the outset. Platform strategies should be supported by standardized assays, robust particle characterization, orthogonal analytical methods, and clear comparability plans for process or formulation changes.

Organizations should build partnerships across hospitals, academic laboratories, diagnostics providers, manufacturers, and regulators; establish governance for AI-enabled decisions; and design development programs that include diverse biological samples and clinically relevant models. Regional execution should account for local infrastructure, workforce, cold-chain requirements, procurement pathways, and reimbursement conditions rather than assuming that one global operating model will fit every setting.

Evidence Synthesis Across Technology, Regulation, Clinical Translation, and Geography

This executive summary uses the supplied market scope-personalized nanotechnology for cell and gene therapies-and organizes the analysis across technology shifts, artificial intelligence, regions, international groups, and specified countries. The framing emphasizes established development considerations, including delivery biology, formulation engineering, quality control, manufacturing, regulatory science, clinical translation, and access.

No market estimates, forecasts, market shares, or company-specific claims are used. Geographic observations are presented as qualitative synthesis and should be validated against current regulatory publications, peer-reviewed studies, clinical-trial records, manufacturing guidance, and national health-policy documents before informing investment or operational decisions.

Responsible Integration Will Determine Whether Personalized Delivery Reaches Patients

Personalized nanotechnology offers a route to more precise and adaptable cell and gene therapies, but scientific novelty alone will not determine outcomes. Success will require evidence that links material properties to clinical benefit, reliable manufacturing at the required level of control, transparent AI use, and regulatory strategies suited to complex individualized products.

The strongest organizations will combine platform flexibility with disciplined validation, regional awareness, and early engagement across the development and care ecosystem. Progress will be most durable when innovation is matched by safety, reproducibility, affordability, equitable access, and credible long-term follow-up.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Personalized Nanotechnology for Cell & Gene Therapies Market, by Therapy Type
7.1. Introduction
7.2. Cell Therapy
7.2.1. Immune Cell Therapy
7.2.2. Induced Pluripotent Stem Cells
7.2.3. Mesenchymal Stem Cells
7.2.4. Stem Cell Therapy
7.3. Gene Therapy
7.3.1. CRISPR Technology
7.3.2. Delivery Mechanisms
7.3.3. Gene Modification Methods
7.3.4. Non-Viral Vectors
8. Personalized Nanotechnology for Cell & Gene Therapies Market, by Nanotechnology Type
8.1. Introduction
8.2. Nanocarrier Design
8.3. Nanodevices
8.4. Nanoencapsulation
8.5. Nanomaterials
8.6. Nanomedicine
8.7. Nanostructure Imaging
9. Personalized Nanotechnology for Cell & Gene Therapies Market, by Application
9.1. Introduction
9.2. Cancer Therapies
9.3. Cardiovascular Diseases
9.4. Inherited Genetic Disorders
9.5. Neurological Disorders
10. Personalized Nanotechnology for Cell & Gene Therapies Market, by End User
10.1. Introduction
10.2. Diagnostic Centers
10.3. Healthcare Facilities
10.4. Pharmaceutical Companies
10.5. Research Institutions
11. Personalized Nanotechnology for Cell & Gene Therapies Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Personalized Nanotechnology for Cell & Gene Therapies Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Personalized Nanotechnology for Cell & Gene Therapies Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. AbbVie Inc.
15.2. Amgen Inc.
15.3. Arcturus Therapeutics, Inc.
15.4. AstraZeneca PLC
15.5. BASF Pharma Solutions
15.6. BlueWillow Biologics Inc.
15.7. Bristol-Myers Squibb Company
15.8. Camurus AB
15.9. Celgene, Inc.
15.10. Cristal Therapeutics
15.11. Cytimmune Sciences
15.12. Eisai Co., Ltd.
15.13. EyePoint Pharmaceuticals
15.14. Gilead Sciences Inc.
15.15. GlaxoSmithKline PLC
15.16. Hoffmann-La Roche Ltd
15.17. Ipsen Pharma
15.18. Johnson & Johnson
15.19. Merck KGaA
15.20. Nanobiotix SA
15.21. Novartis AG
15.22. Pfizer Inc.
15.23. Spark Therapeutics, Inc.
15.24. Teva Pharmaceutical Industries Limited
15.25. Thermo Fisher Scientific Inc.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Personalized Nanotechnology for Cell & Gene Therapies Market, Years Considered for the Study
FIGURE 2. Global Personalized Nanotechnology for Cell & Gene Therapies Market, Research Design
FIGURE 3. Global Personalized Nanotechnology for Cell & Gene Therapies Market, Research Framework
FIGURE 4. Global Personalized Nanotechnology for Cell & Gene Therapies Market, Data Triangulation
FIGURE 5. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2025 vs 2032 (%)
FIGURE 7. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2025 vs 2032 (%)
FIGURE 9. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2025 vs 2032 (%)
FIGURE 11. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Personalized Nanotechnology for Cell & Gene Therapies Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Personalized Nanotechnology for Cell & Gene Therapies Market Segmentation & Coverage
TABLE 2. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, 2017-2032 (USD Million)
TABLE 3. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 4. Global Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Immune Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Immune Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Immune Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Induced Pluripotent Stem Cells Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Induced Pluripotent Stem Cells Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Induced Pluripotent Stem Cells Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Mesenchymal Stem Cells Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Mesenchymal Stem Cells Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Mesenchymal Stem Cells Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Stem Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Stem Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Stem Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global CRISPR Technology Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global CRISPR Technology Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global CRISPR Technology Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Delivery Mechanisms Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Delivery Mechanisms Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Delivery Mechanisms Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Gene Modification Methods Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Gene Modification Methods Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Gene Modification Methods Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Non-Viral Vectors Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Non-Viral Vectors Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Non-Viral Vectors Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 35. Global Nanocarrier Design Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Nanocarrier Design Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Nanocarrier Design Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Nanodevices Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Nanodevices Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Nanodevices Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Nanoencapsulation Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Nanoencapsulation Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Nanoencapsulation Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Nanomaterials Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Nanomaterials Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Nanomaterials Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Nanomedicine Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Nanomedicine Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Nanomedicine Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Nanostructure Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Nanostructure Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Nanostructure Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 54. Global Cancer Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Cancer Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Cancer Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Cardiovascular Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Cardiovascular Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Cardiovascular Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Inherited Genetic Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Inherited Genetic Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Inherited Genetic Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Neurological Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Neurological Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Neurological Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 67. Global Diagnostic Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Diagnostic Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Diagnostic Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Healthcare Facilities Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Healthcare Facilities Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Healthcare Facilities Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Research Institutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Research Institutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Research Institutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Asia-Pacific Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Asia-Pacific Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 82. Asia-Pacific Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 83. Asia-Pacific Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 84. Asia-Pacific Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 85. Asia-Pacific Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 86. Asia-Pacific Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 87. North America Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. North America Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 89. North America Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 90. North America Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 91. North America Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 92. North America Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 93. North America Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 94. Latin America Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Latin America Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 96. Latin America Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 97. Latin America Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 98. Latin America Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 99. Latin America Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 100. Latin America Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 101. Europe Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Europe Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 103. Europe Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 104. Europe Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 105. Europe Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 106. Europe Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 107. Europe Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 108. Middle East Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Middle East Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 110. Middle East Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 111. Middle East Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 112. Middle East Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 113. Middle East Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 114. Middle East Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 115. Africa Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Africa Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 117. Africa Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 118. Africa Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 119. Africa Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 120. Africa Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 121. Africa Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 122. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. ASEAN Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. ASEAN Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 125. ASEAN Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 126. ASEAN Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 127. ASEAN Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 128. ASEAN Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 129. ASEAN Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. GCC Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 131. GCC Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 132. GCC Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 133. GCC Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 134. GCC Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 135. GCC Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 136. GCC Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 137. European Union Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 138. European Union Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 139. European Union Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 140. European Union Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 141. European Union Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 142. European Union Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 143. European Union Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 144. BRICS Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. BRICS Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 146. BRICS Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 147. BRICS Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 148. BRICS Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 149. BRICS Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 150. BRICS Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. G7 Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 152. G7 Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 153. G7 Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 154. G7 Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 155. G7 Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 156. G7 Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 157. G7 Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 158. NATO Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 159. NATO Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 160. NATO Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 161. NATO Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 162. NATO Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 163. NATO Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 164. NATO Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 165. Global Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 166. United States Personalized Nanotechnology for Cell & Gene Therapies Market Size, 2017-2032 (USD Million)
TABLE 167. United States Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 168. United States Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 169. United States Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 170. United States Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 171. United States Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 172. United States Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 173. Canada Personalized Nanotechnology for Cell & Gene Therapies Market Size, 2017-2032 (USD Million)
TABLE 174. Canada Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 175. Canada Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 176. Canada Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 177. Canada Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 178. Canada Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 179. Canada Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 180. Mexico Personalized Nanotechnology for Cell & Gene Therapies Market Size, 2017-2032 (USD Million)
TABLE 181. Mexico Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 182. Mexico Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 183. Mexico Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 184. Mexico Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 185. Mexico Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 186. Mexico Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. Brazil Personalized Nanotechnology for Cell & Gene Therapies Market Size, 2017-2032 (USD Million)
TABLE 188. Brazil Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 189. Brazil Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 190. Brazil Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 191. Brazil Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 192. Brazil Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 193. Brazil Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 194. United Kingdom Personalized Nanotechnology for Cell & Gene Therapies Market Size, 2017-2032 (USD Million)
TABLE 195. United Kingdom Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 196. United Kingdom Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 197. United Kingdom Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 198. United Kingdom Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 199. United Kingdom Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 200. United Kingdom Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 201. Germany Personalized Nanotechnology for Cell & Gene Therapies Market Size, 2017-2032 (USD Million)
TABLE 202. Germany Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 203. Germany Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 204. Germany Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 205. Germany Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 206. Germany Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 207. Germany Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. France Personalized Nanotechnology for Cell & Gene Therapies Market Size, 2017-2032 (USD Million)
TABLE 209. France Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 210. France Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 211. France Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 212. France Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 213. France Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 214. France Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 215. Russia Personalized Nanotechnology for Cell & Gene Therapies Market Size, 2017-2032 (USD Million)
TABLE 216. Russia Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 217. Russia Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 218. Russia Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 219. Russia Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 220. Russia Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 221. Russia Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 222. Italy Personalized Nanotechnology for Cell & Gene Therapies Market Size, 2017-2032 (USD Million)
TABLE 223. Italy Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 224. Italy Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 225. Italy Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 226. Italy Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 227. Italy Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 228. Italy Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 229. Spain Personalized Nanotechnology for Cell & Gene Therapies Market Size, 2017-2032 (USD Million)
TABLE 230. Spain Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 231. Spain Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 232. Spain Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 233. Spain Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 234. Spain Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 235. Spain Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 236. China Personalized Nanotechnology for Cell & Gene Therapies Market Size, 2017-2032 (USD Million)
TABLE 237. China Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 238. China Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 239. China Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 240. China Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 241. China Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 242. China Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 243. India Personalized Nanotechnology for Cell & Gene Therapies Market Size, 2017-2032 (USD Million)
TABLE 244. India Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 245. India Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 246. India Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 247. India Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 248. India Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 249. India Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 250. Japan Personalized Nanotechnology for Cell & Gene Therapies Market Size, 2017-2032 (USD Million)
TABLE 251. Japan Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 252. Japan Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 253. Japan Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 254. Japan Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 255. Japan Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 256. Japan Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 257. Australia Personalized Nanotechnology for Cell & Gene Therapies Market Size, 2017-2032 (USD Million)
TABLE 258. Australia Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 259. Australia Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 260. Australia Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 261. Australia Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 262. Australia Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 263. Australia Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 264. South Korea Personalized Nanotechnology for Cell & Gene Therapies Market Size, 2017-2032 (USD Million)
TABLE 265. South Korea Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 266. South Korea Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 267. South Korea Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 268. South Korea Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Nanotechnology Type, 2017-2032 (USD Million)
TABLE 269. South Korea Personalized Nanotechnology for Cell & Gene Therapies Market Size, by Application, 2017-2032 (USD Million)
TABLE 270. South Korea Personalized Nanotechnology for Cell & Gene Therapies Market Size, by End User, 2017-2032 (USD Million)
TABLE 271. Global Personalized Nanotechnology for Cell & Gene Therapies Market Share, by Key Player, 2025
TABLE 272. Global Personalized Nanotechnology for Cell & Gene Therapies Market, Key Experts

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Arcturus Therapeutics, Inc.
  • AstraZeneca PLC
  • BASF Pharma Solutions
  • BlueWillow Biologics Inc.
  • Bristol-Myers Squibb Company
  • Camurus AB
  • Celgene, Inc.
  • Cristal Therapeutics
  • Cytimmune Sciences
  • Eisai Co., Ltd.
  • EyePoint Pharmaceuticals
  • Gilead Sciences Inc.
  • GlaxoSmithKline PLC
  • Hoffmann-La Roche Ltd
  • Ipsen Pharma
  • Johnson & Johnson
  • Merck KGaA
  • Nanobiotix SA
  • Novartis AG
  • Pfizer Inc.
  • Spark Therapeutics, Inc.
  • Teva Pharmaceutical Industries Limited
  • Thermo Fisher Scientific Inc.

Related Topics

Related Reports

Personalized Cell & Gene Therapies Market - Global Forecast 2026-2032 - Product Image

Personalized Cell & Gene Therapies Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Cell & Gene Therapy Manufacturing Services Market - Global Forecast 2026-2032 - Product Image

Cell & Gene Therapy Manufacturing Services Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Cancer Gene Therapy - Global Strategic Business Report - Product Image

Cancer Gene Therapy - Global Strategic Business Report

  • Report
  • 237 Pages
  • Global
From
Cell and Gene Therapy Clinical Trial Services - Global Strategic Business Report - Product Image

Cell and Gene Therapy Clinical Trial Services - Global Strategic Business Report

  • Report
  • 154 Pages
  • Global
From
Cell Gene Therapy CDMO Market - Product Image

Cell Gene Therapy CDMO Market

  • Report
  • 80 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.